Texas Permanent School Fund Corp Buys 146 Shares of Edwards Lifesciences Co. (NYSE:EW)

Texas Permanent School Fund Corp grew its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 0.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 125,369 shares of the medical research company’s stock after purchasing an additional 146 shares during the period. Texas Permanent School Fund Corp’s holdings in Edwards Lifesciences were worth $11,980,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. DSM Capital Partners LLC purchased a new position in Edwards Lifesciences during the 4th quarter valued at about $28,000. Turtle Creek Wealth Advisors LLC purchased a new position in Edwards Lifesciences during the 4th quarter valued at about $34,000. Riverview Trust Co purchased a new position in Edwards Lifesciences during the 1st quarter valued at about $34,000. Pingora Partners LLC purchased a new position in Edwards Lifesciences during the 4th quarter valued at about $38,000. Finally, Burkett Financial Services LLC purchased a new position in Edwards Lifesciences during the 4th quarter valued at about $46,000. Institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the subject of several recent analyst reports. The Goldman Sachs Group initiated coverage on shares of Edwards Lifesciences in a report on Thursday, May 30th. They issued a “buy” rating and a $107.00 target price for the company. Evercore ISI lifted their target price on shares of Edwards Lifesciences from $89.00 to $91.00 and gave the stock an “in-line” rating in a report on Tuesday, July 2nd. Mizuho lifted their target price on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, April 11th. Morgan Stanley lifted their target price on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a report on Thursday, March 21st. Finally, OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $95.24.

Edwards Lifesciences Stock Performance

NYSE EW traded down $1.11 during trading hours on Friday, hitting $91.74. 275,134 shares of the company’s stock traded hands, compared to its average volume of 3,373,311. The business’s fifty day moving average price is $88.86 and its two-hundred day moving average price is $86.26. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $55.28 billion, a P/E ratio of 40.02, a P/E/G ratio of 3.43 and a beta of 1.11. Edwards Lifesciences Co. has a 52 week low of $60.57 and a 52 week high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.02. The company had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. Equities research analysts predict that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total value of $466,450.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $4,378,659.44. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total value of $466,450.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $4,378,659.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Michael A. Mussallem sold 29,350 shares of the business’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $84.77, for a total transaction of $2,487,999.50. Following the completion of the transaction, the director now directly owns 4,486 shares in the company, valued at approximately $380,278.22. The disclosure for this sale can be found here. Insiders sold a total of 81,099 shares of company stock worth $7,003,553 over the last three months. 1.29% of the stock is currently owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.